Overview A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer Status: RECRUITING Trial end date: 2025-12-01 Target enrollment: Participant gender: Summary Phase I and multicenter study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with clear cell renal cell carcinoma.Phase: PHASE1 Details Lead Sponsor: Philogen S.p.A.